Neoadjuvant Treatment Real-world Clinical Outcomes in NSCLC: A Retrospective Multi-center Study (NeoR-World)
Despite the clinical success of immune checkpoint blockade (ICB), in neoadjuvant setting, there is still a lack of valid data for operable NSCLC in the real world. This study aim to compare the clinical outcomes (pathologic response rate versus survival) of neoadjuvant immunochemotherapy with neoadjuvant chemotherapy in the real world, to explore the impact of clinicopathological factors on clinical outcomes in neoadjuvant immunochemotherapy setting, and to identify potential neoadjuvant immunochemotherapy beneficiaries.
• Cytological or histological diagnosis of non-small cell lung cancer
• Patients who have previously undergone neoadjuvant immune checkpoint inhibitors and/or chemotherapy and then undergone radical surgery;
• Stage I-III non-small cell lung cancer (IASLC/UICC staging eighth edition);
• No previous history of malignant tumors and other malignant tumors at the same time, without any anti-tumor treatment;
• ECOG score 0-1, heart, lung, liver, brain and kidney function can tolerate surgery;
• At least one measurable lesion (RECIST v1.1);
• Age \>= 18 years old and \<= 85 years old;
• Be able to abide by the visits and related procedures stipulated in the program.